ATRC

AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.

AtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC Matthew O'Brien - Piper Sandler & Co., Research Division John Young - Canaccord Genuity Corp., Research Division Marie Thibault - BTIG, LLC, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Third Quarter 2026 Earnings Conference Call.

During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.